Department of Ophthalmology, The Second Hospital of Jilin University, Jilin University, Changchun, China.
Int J Biol Sci. 2022 Aug 29;18(14):5405-5414. doi: 10.7150/ijbs.75876. eCollection 2022.
Fibrosis is a detrimental outcome of most chronic inflammatory disorders and is defined by the buildup of excess extracellular matrix (ECM) components, which eventually leads to organ failure and death. Interleukin 6 (IL-6) is promptly produced by immune cells in response to tissue injuries and has a wide range of effects on cellular processes such as acute responses, hematopoiesis, and immune reactions. Furthermore, high levels of IL-6 have been found in a variety of chronic inflammatory disorders characterized by fibrosis, and this factor plays a significant role in fibrosis in various organs via Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) activation. Here, we review what is known about the role of IL-6 in fibrosis and why targeting IL-6 for fibrotic disease treatment makes sense.
纤维化是大多数慢性炎症性疾病的有害后果,其特征是细胞外基质 (ECM) 成分的过度积累,最终导致器官衰竭和死亡。白细胞介素 6 (IL-6) 是免疫细胞对组织损伤的快速反应产物,对细胞过程有广泛的影响,如急性反应、造血和免疫反应。此外,在多种以纤维化为特征的慢性炎症性疾病中发现高水平的 IL-6,该因子通过 Janus 激酶/信号转导和转录激活因子 3 (JAK/STAT3) 激活在各种器官的纤维化中起重要作用。在这里,我们回顾了 IL-6 在纤维化中的作用以及为什么针对 IL-6 进行纤维性疾病治疗是有意义的。